

<b>Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/528,691	KARUP ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Celia Chang	1625	

All participants (applicant, applicant's representative, PTO personnel):

(1) Celia Chang. (3)\_\_\_\_\_.

(2) Keiko K. Takagi. (4)\_\_\_\_\_.

Date of Interview: 29 April 2010.

Type: a)☒ Telephonic b)☐ Video Conference  
c)☐ Personal [copy given to: 1)☐ applicant 2)☐ applicant's representative]

Exhibit shown or demonstration conducted: d)☐ Yes e)☐ No.  
If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: 4 and 21.

Identification of prior art discussed: n/a.

Agreement with respect to the claims f)☐ was reached. g)☐ was not reached. h)☒ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

	/Celia Chang/ Primary Examiner, Art Unit 1625
--	--

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The examiner explained that although applicants presented data in an affidavit that the the "D,L-lactate hemihydrate" or L-lactate 1/4-hydrate" are anhydrous. MPEP 608.01(q) requires that applicants declare that the amendment contains "no new matter". To support no new matter was added when the specification is amended, applicants must provide affidavit stating that "when" was the error discovered, "what" was the "factual support" that the identity of the product was erroneous and "why" the new identity is within the four corner of the specification as originally filed. In chemical formula, it is understood that DL raloxifene lactate hemihydrate is a different product from DL-raloxifene lactate anhydrous.

/